Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-97540 in Autoimmune Neurological Diseases
NCT06220201Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Primary completion
- Jul 2027
- Countries
- 6
01
Overview
Phase 1, open-label trial of BMS-986353 in multiple sclerosis (MS) and myasthenia gravis (MG) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events at 104 weeks, Number of participants with serious adverse events at 104 weeks and 5 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
BMS-986353
03
Conditions
multiple sclerosis (MS)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06220201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220201.